Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HM10660A in Chronic Hepatitis C
NCT02057887Phase 2Unknown
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jul 2013
- Primary completion
- Aug 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of HM10660A in hepatitis C (HCV) (4 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: HCV RNA Viral load at Week 32 and Safety and tolerability at Week 32. Status: unknown.
02
Drugs
HM10660A
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02057887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02057887.